Wei Hongshan, Zhang Jing, Li Hongmin, Ren Hui, Hao Xiaohua, Huang Yubo
Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Beijing Youan Hospital, Capital Medical University, Beijing 100039, China.
Diagn Microbiol Infect Dis. 2014 May;79(1):19-24. doi: 10.1016/j.diagmicrobio.2014.01.008. Epub 2014 Jan 24.
Although Golgi protein 73 (GP73) has been widely evaluated for diagnosing hepatocellular carcinoma (HCC) and other liver diseases in recent decade, its serum profile of patients with hepatitis B virus (HBV)-associated acute-on-chronic liver failure (HBV-ACLF) is still unknown. This study was designed to evaluate the serum levels of GP73 in patients with HBV-ACLF. The participants included 200 apparently healthy controls; 200 patients with chronic hepatitis B (CHB); 200 patients with HCC; 210 patients with HBV-ACLF, in which 29 HBV-ACLF patients were followed up for 3 months. All patients were Hepatitis B virus surface antigen (HBsAg) positive. The concentrations of GP73 in patients with HBV-ACLF (285.3 ± 128.5 ng/mL) were markedly higher than those HCC patients (159.1 ± 105.8 ng/mL), CHB patients (64.65 ± 44.99 ng/mL), and healthy controls (35.37 ± 12.41 ng/mL). When the cut-off value was set at 182.1 ng/mL, the sensitivity and specificity of HBV-ACLF diagnosis were 77.62% (95% confidence interval [CI]: 71.37%-83.07%) and 95.50% (95% CI: 92.27%-98.26%), respectively. If serum GP73 concentration was still above 361.6 ng/mL after 14 days of follow-up, the patient's prognosis may be depressed. Serum GP73 may be used to diagnosis HBV-ACLF in population with chronic HBV infections.
尽管近十年来高尔基体蛋白73（GP73）已被广泛用于诊断肝细胞癌（HCC）和其他肝脏疾病，但其在乙型肝炎病毒（HBV）相关慢加急性肝衰竭（HBV-ACLF）患者中的血清特征仍不清楚。本研究旨在评估HBV-ACLF患者的血清GP73水平。研究对象包括200名健康对照者；200名慢性乙型肝炎（CHB）患者；200名HCC患者；210名HBV-ACLF患者，其中29名HBV-ACLF患者进行了3个月的随访。所有患者乙型肝炎病毒表面抗原（HBsAg）均为阳性。HBV-ACLF患者的GP73浓度（285.3±128.5 ng/mL）明显高于HCC患者（159.1±105.8 ng/mL）、CHB患者（64.65±44.99 ng/mL）和健康对照者（35.37±12.41 ng/mL）。当临界值设定为182.1 ng/mL时，HBV-ACLF诊断的敏感性和特异性分别为77.62%（95%置信区间[CI]：71.37%-83.07%）和95.50%（95%CI：92.27%-98.26%）。随访14天后，如果血清GP73浓度仍高于361.6 ng/mL，则患者的预后可能较差。血清GP73可用于诊断慢性HBV感染人群中的HBV-ACLF。
